Clinical Trials Browser

Phase 2 × Interventional × siltuximab × Clear all

NCT06470971 2026-01-20

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

Phase 2 Recruiting

Other solid neoplasm

Advanced Malignant Solid Neoplasm

NCT03315026 2025-11-04

Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis

Phase 2 Active not recruiting

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma

NCT05684692 2025-10-30

Screening Trial for Pain Relief in Schwannomatosis (STARFISH)

Phase 2 Recruiting

Schwannomatosis, Neurilemmoma, Pain, Chronic Pain

NCT04975555 2025-09-22

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

Phase 2 Active not recruiting

LymphoidOther hematologic neoplasmPlasma cell

Cytokine Release Syndrome, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07106671 2025-08-06

A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma

Phase 2 Recruiting

Cytokine Release Syndrome, Neoplasms, Plasma Cell

NCT06352866 2025-03-03

Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM

Phase 2 Withdrawn

Cytokine Release Syndrome, Multiple Myeloma

NCT01484275 2020-01-27

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Phase 2 Completed

85 enrolled 15 charts

Multiple Myeloma

NCT00401843 2019-11-19

A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

Phase 2 Completed

307 enrolled 13 charts

Multiple Myeloma

NCT00911859 2014-11-18

A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients

Phase 2 Completed

118 enrolled 16 charts

Multiple Myeloma

NCT00385827 2014-08-20

A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)

Phase 2 Terminated

106 enrolled 13 charts

Neoplasms, Prostatic Neoplasms

NCT00402181 2014-05-14

An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00311545 2013-02-20

S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer

Phase 2 Withdrawn

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00433446 2013-02-05

S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Phase 2 Completed

62 enrolled 13 charts

Prostatic Neoplasms